GC Biopharma and Hanmi Pharm's jointly developed new drug licensed to US BioMarin
Predicted impact: Medium
Technology export up to $475M; about 640B won deal already reported earlier, roughly 39% of market value.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.